Business Standard

Dr Reddy's Laboratories eyes place among top five domestic pharma players

The US would continue to remain an important geography, but the firm says it hopes to double its revenues from China and grow revenues five-fold in Brazil in the next five years

Dr Reddy's
Premium

Dr Reddy's

Sohini Das Mumbai
Hyderabad-based Dr Reddy’s Laboratories (DRL) is aiming to be among the top-five pharma players in the domestic market by focusing on the chronic therapy segment. The US would continue to remain an important geography, but the firm says it hopes to double its revenues from China and grow revenues five-fold in Brazil in the next five years.

The firm has outlined an ambitious strategy for its next leg of growth where it says by 2027; at least 25 per cent of its products will be “first to market” generics, which means they will be affordable versions of innovator products. (see

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 24 2022 | 1:39 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com